Compare Mongodb Inc (MDB) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mongodb Inc vs TransMedics Group Inc — how do they compare? Mongodb Inc trades at $385.93 (market cap $29.24B), while TransMedics Group Inc trades at $77.87 (market cap $2.74B). The key difference: Mongodb Inc is far larger — about 10.7× TransMedics Group Inc's market cap, and Mongodb Inc is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Mongodb Inc for 46 Days and TransMedics Group Inc for 24 Days on average.
| MDB | TMDX | |
|---|---|---|
Market Cap | $29.24B | $2.74B |
Volume | 1,304,995 | 949,331 |
Sector | Technology | Health |
52-Week High | $472.29 | $150.42 |
52-Week Low | $225.95 | $61.99 |
Typical Hold Time | 46 Days | 24 Days |
Enterprise Value | $26.86B | $3.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MongoDB (MDB) trades at $371.35, up 2.29% today, showing strong momentum after recent volatility. The stock maintains bullish technical signals with support at $366 and resistance at $375. Fundamentally, revenue growth remains robust at $2.01B for 2025, though the company continues to report net losses. Recent investor day highlighted AI product launches and raised long-term targets, offsetting concerns about CEO transition. Analyst consensus remains strongly bullish with 80% buy ratings and $456.76 price target, representing 23% upside potential.
MDB presents a growth investment opportunity with significant AI-driven upside potential, though elevated valuation metrics (P/E 511) and ongoing profitability challenges warrant caution. The company's strategic focus on AI infrastructure and enterprise partnerships supports long-term growth narrative, but execution risks during leadership transition and competitive pressures in database markets require monitoring. Current technical setup favors near-term strength with proper risk management.
TMDX trades at $79.00, down 2.55% amid bearish technical signals. The stock shows strong profitability with 22.69% net margin and 36.28% ROE, though recent earnings misses and margin compression from 2025 to 2026 raise concerns. Analyst consensus remains bullish with a $99.75 price target, but multiple legal investigations into fiduciary duties create uncertainty. Revenue growth continues with 2026 guidance at $668M.
The stock presents a growth opportunity with analyst upside potential, but faces near-term headwinds from earnings volatility and legal scrutiny. Execution on 2026 guidance and resolution of governance concerns will be critical for sustained momentum. Current valuation at 20.47 P/E appears reasonable given growth prospects if operational targets are met.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Mongodb Inc
Founded in 2007, MongoDB is a document-oriented database with nearly 33,000 paying customers and well past 1.5 million free users. MongoDB provides both licenses as well as subscriptions as a service for its NoSQL database. MongoDB's database is compatible with all major programming languages and is capable of being deployed for a variety of use cases.
Read more on MDB →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
